Key result
Factor XI/XIa inhibitors show promise for preventing clots without increasing bleeding vs standard anticoagulants.
Why the study?
Modern-day anticoagulants predispose patients to pathological bleeding, prompting research into Factor XI/XIa inhibitors to minimize bleeding risks while preventing clot formation.
Do Factor XI/XIa inhibitors prevent blood clot formation without increasing bleeding compared to modern-day anticoagulants in patients requiring anticoagulation?
Comparison
Factor XI/XIa inhibitors vs modern-day anticoagulants
Design
Review
Authors
Loading...
May support enrollment in phase III trials for high-risk patients; leaves open net clinical benefit versus current anticoagulants.
Do Factor XI/XIa inhibitors prevent blood clot formation without increasing bleeding compared to modern-day anticoagulants in patients requiring anticoagulation?
Factor XI/XIa inhibitors represent a novel approach to anticoagulation that may decouple thrombosis prevention from bleeding risk.
Whiteson et al. (2023) conducted a review in Cardiovascular disease requiring anticoagulation. Factor XI/XIa inhibitors was evaluated. Factor XI/XIa inhibitors are an emerging class of anticoagulants in phase II and III trials that show promise in preventing blood clot formation without increasing bleeding events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: